May 3, 2021 /

Webinar: Viltepso – A Treatment Option for Patients Amenable to Exon 53 Skipping (April 22, 2021)

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

NS Pharma joined PPMD for a webinar on April 22, 2021 to provide an update about VILTEPSO™, a treatment of Duchenne in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, and its associated patient support program.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo